Cancer Is A Genetic Disease

Cancer Is A Genetic Disease.
When actress Angelina Jolie went noted about her counteractive double mastectomy, it did not lead to an increased understanding of the genetic risk of bust cancer, researchers say. Although it raised awareness of breast cancer, exposure to Jolie's feature may have resulted in greater confusion about the link between a family history of breast cancer and increased cancer risk, according to the study, published Dec 19, 2013 in the record Genetics in Medicine. Earlier this year, Jolie revealed that she had both breasts removed after culture that she carried a mutation in a gene called BRCA1 that is linked to tit and ovarian cancers.

Women with mutations in that gene and the BRCA2 gene have a five times higher danger of breast cancer and a 10 to 30 times higher imperil of developing ovarian cancer than those without the mutations. For the study, researchers surveyed more than 2500 Americans. About 75 percent were knowledgeable of Jolie's story, the investigators found. But fewer than 10 percent of the respondents could correctly meet questions about the BRCA gene changing that Jolie carries and the typical woman's risk of developing breast cancer.

So "Ms Jolie's salubrity story was prominently featured throughout the media and was a chance to mobilize health communicators and educators to tutor about the nuanced issues around genetic testing, risk and preventive surgery," study govern author Dina Borzekowski, a research professor in the University of Maryland School of Public Health's concern of behavior and community health, said in a university news release. However, it "feels delight in it was a missed opportunity to educate the public about a complex but rare health situation".

Scientists Spot Genetic Traces of Individual Cancers

Scientists Spot Genetic Traces of Individual Cancers.
Researchers have found a modus operandi to analyze the speck of a cancer, and then use that trace to track the trajectory of that particular tumor in that particular person. "This facility will allow us to measure the amount of cancer in any clinical specimen as soon as the cancer is identified by biopsy," said reflect on co-author Dr Luis Diaz, an assistant professor of oncology at Johns Hopkins University.

And "This can then be scanned for gene rearrangements, which will then be second-hand as a template to track that exacting cancer." Diaz is one of a group of researchers from the Ludwig Center for Cancer Genetics and Therapeutics and the Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center that sign in on the idea in the Feb 24 issue of Science Translational Medicine. This latest finding brings scientists one motion closer to personalized cancer treatments, experts say.

But "These researchers have determinate the entire genomic sequence of several breast and colon cancers with great precision," said Katrina L Kelner, the journal's editor. "They have been able to connect small genomic rearrangements single to that tumor and, by following them over time, have been able to follow the course of the disease." One of the biggest challenges in cancer care is being able to see what the cancer is doing after surgery, chemo or radiation and, in so doing, help guide therapy decisions. "Some cancers can be monitored by CT scans or other imaging modalities, and a few have biomarkers you can follow in the blood but, to date, no infinite method of accurate surveillance exists," Diaz stated.

Almost all anthropoid cancers, however, exhibit "rearrangement" of their chromosomes. "Rearrangements are the most dramatic form of genetic changes that can occur," lucubrate co-author Dr Victor Velculescu explained, likening these arrangements to the chapters of a enlist being out of order. This type of mistake is much easier to recognize than a mere typo on one page.

New Methods In The Study Of Breast Cancer

New Methods In The Study Of Breast Cancer.
An theoretical blood assess could help show whether women with advanced breast cancer are responding to treatment, a beginning study suggests. The test detects abnormal DNA from tumor cells circulating in the blood. And the novel findings, reported in the March 14 issue of the New England Journal of Medicine, signal that it could outperform existing blood tests at gauging some women's feedback to treatment for metastatic breast cancer. That's an advanced form of breast cancer, where tumors have jelly to other parts of the body - most often the bones, lungs, liver or brain.

There is no cure, but chemotherapy, hormonal psychoanalysis or other treatments can slow disease progression and ease symptoms. The sooner doctors can advise whether the treatment is working, the better. That helps women avoid the plane effects of an ineffective therapy, and may enable them to switch to a better one.

Right now, doctors monitor metastatic chest cancer with the help of imaging tests, such as CT scans. They may also use certain blood tests - including one that detects tumor cells floating in the bloodstream, and one that measures a tumor "marker" called CA 15-3.

But imaging does not charge the sound story, and it can expose women to significant doses of radiation. The blood tests also have limitations and are not routinely used. "Practically speaking, there's a leviathan miss for novel methods" of monitoring women, said Dr Yuan Yuan, an aid professor of medical oncology at City of Hope cancer center in Duarte, Calif.

For the changed study, researchers at the University of Cambridge in England took blood samples from 30 women being treated for metastatic knocker cancer and having standard imaging tests. They found that the tumor DNA exam performed better than either the CA 15-3 or the tumor cell check when it came to estimating the women's treatment response. Of 20 women the researchers were able to follow for more than 100 days, 19 showed cancer course on their CT scans.

And 17 of them had shown rising tumor DNA levels. In contrast, only seven had a rising million of tumor cells, while nine had an increase in CA 15-3 levels. For 10 of those 19 women, tumor DNA was on the occur an typical of five months before CT scans showed their cancer was progressing. "The take-home message is that circulating tumor DNA is a better monitoring biomarker than the existing Food and Drug Administration-approved ones," said elder researcher Dr Carlos Caldas.

Scientists Have Found The Effect Of Silica On The Lungs

Scientists Have Found The Effect Of Silica On The Lungs.
More vigour is needed to demote illness and death among the millions of Americans exposed to silica dust at work, according to a reborn report Dec, 2013. It has large been known that silica - a natural substance found in most rocks, sand and clay - causes the lung cancer silicosis, and evidence has mounted in recent decades that silica causes lung cancer, said come in co-author Kyle Steenland, of the School of Public Health at Emory University. "Current regulations have at bottom reduced silicosis death rates in the United States, but additional cases of silicosis continue to be diagnosed".

Recommended measures include stronger regulations, increased awareness and prevention, and greater prominence to early detection of silicosis and lung cancer using low-dose CT scanning, the researchers said in the prevailing issue of CA: A Cancer Journal for Clinicians. "While the lung cancer peril associated with silica exposure is not as large as some other lung carcinogens, equal smoking or asbestos exposure, there is strong and consistent evidence that silica hazard increases lung cancer risk," Steenland said in a journal news release.

Very Few People Over Age 50 Are Diagnosed By Detection Of Skin Cancer

Very Few People Over Age 50 Are Diagnosed By Detection Of Skin Cancer.
Too few middle-aged and older snow-white Americans are being screened for bark cancer, a exact problem among those who did not finish high school or receive other banal cancer screenings, a new study has found. Researchers analyzed data from 10,486 ghostly men and women, aged 50 and older, who took part in the 2005 National Health Interview Survey.

Only 16 percent of men and 13 percent of women reported having a coat research in the past year. The lowest rates of skin cancer screenings were amongst men and women aged 50 to 64, people with some high school cultivation or less, those without a history of skin cancer, and those who hadn't had a recent screening for breast cancer, prostate cancer or colorectal cancer.

So "With those older than 50 being at a higher gamble for developing melanoma, our memorize results clearly indicate that more intervention is needed in this population," study author Elliot J Coups, a behavioral scientist at the Cancer Institute of New Jersey and an confederate professor of remedy at UMDNJ-Robert Wood Johnson Medical School, said in a news release from the institute. "Of itemized interest is the amount of education one has and how that may affect whether a person is screened or not screened for hide cancer.

Is it a matter of a person not knowing the importance of such an examination or where to get such a screening and from whom? Is it a occasion of one's insurance not covering a dermatologist or there being no coverage at all? We are hopeful this study leads to further confabulation among health-care professionals, particularly among community physicians, about what steps can be entranced to ensure their patients are receiving information on skin cancer screening and are being presented with opportunities to come into that examination". Skin cancer is the most common of all cancers, according to the American Cancer Society.

Despite The Risk Of Skin Cancer Sun Decks Still Popular

Despite The Risk Of Skin Cancer Sun Decks Still Popular.
Tanning bed use remains current among Americans, a new study shows, without considering reported links to an increased risk of skin cancer and the availability of safe "spray-on" tans. In fact, about one in every five women and more than 6 percent of men command they use indoor tanning, University of Minnesota researchers report. "Tanning is common, principally among children women," said study author Kelvin Choi, a research associate from the university's School of Public Health. "The use of tanning is indeed higher than smoking".

And "People tan for excellent reasons," said Dr Cheryl Karcher, a dermatologist and educational spokeswoman for The Skin Cancer Foundation. "A lot of family feel they look better with a little bit of color. Eventually, society will realize that the skin you were born with is the skin that looks best on you".

Karcher noted that there is no safe even of tanning. "Ultraviolet light damages the DNA of cells and makes cancer. People should utterly avoid indoor tanning. There is absolutely no reason for it. In the long run, it's in the end harmful".

Yet, many seem unaware of the risk for skin cancer linked to tanning beds and don't take to be avoiding them as a way to reduce their risk of skin cancer, the researchers noted. That's wretched because "the popularity of indoor tanning among young women may bestow to the recent increase of melanoma in women under 40".

The report is published in the December issue of the Archives of Dermatology. Skin cancer is the most standard form of cancer in the United States. According to the American Cancer Society, in 2009 there were about 1 million changed cases of melanoma and non-melanoma hide cancer and about 8650 Americans died from melanoma, the most deadly form of skin cancer.

Numerous studies have linked indoor tanning to a heightened danger of skin cancer, including one study published in May that found that tanning bed use boosts the disparity for melanoma. Early this year, an advisory panel to the US Food and Drug Administration also recommended a taboo on the use of tanning beds by people under the era of 18.

Some Hope For A Vaccine Against The Advanced Stages Of Cancer

Some Hope For A Vaccine Against The Advanced Stages Of Cancer.
Scientists have genetically tweaked an virus to the latest a healthy vaccine that appears to start a variety of advanced cancers. The vaccine has provoked the required tumor-fighting vaccinated response in early human trials, but only in a minority of patients tested. And one expert urged caution. "They were able to make an immune response with the vaccine. That's a good thing but we fundamental a little more information," said Dr Adam Cohen, assistant professor in medical oncology at Fox Chase Cancer Center in Philadelphia.

He was not snarled in the study. "This is the first contemplation in cancer patients with this type of vaccine, with a relatively small number of patients treated so far. So while the untouched response data are promising, further study in a larger number of patients will be required to assess the clinical promote of the vaccine".

One vaccine to treat prostate cancer, Provenge, was recently approved by the US Food and Drug Administration. However, Cohen respected that many other cancer vaccines have shown advanced promise and not panned out.

The theory behind therapeutic cancer vaccines is that people with cancer gravitate to have defects in their immune system that compromise their ability to respond to malignancy, explained exploration lead author Dr Michael Morse, associate professor of medicine at Duke University Medical Center. "A vaccine has to implement by activating immune cells that are capable of decimation tumors and those immune cells have to survive long enough to get to the tumor and destroy it".

E-Mail Reminder To The Survey

E-Mail Reminder To The Survey.
Both electronic and mailed reminders alleviate aid some patients to get colorectal cancer screenings, two new studies show. One work included 1103 patients, aged 50 to 75, at a group work who were overdue for colorectal cancer screening. Half of them received a single electronic message from their doctor, along with a relate to a Web-based tool to assess their risk for colorectal cancer. The other patients acted as a button group and did not receive any electronic messages. One month later, the screening rates were 8,3 percent for patients who received the electronic reminders and 0,2 percent in the be in control group.

But the imbalance was no longer significant after four months - 15,8 percent vs 13,1 percent. Among the 552 patients who received the electronic message, 54 percent viewed it and 9 percent worn the Web-based assessment tool. About one-fifth of the patients who occupied the assessment way were estimated to have a higher-than-average risk for colorectal cancer.

Patients who used the risk tool were more probable to get screened. "Patients have expressed interest in interacting with their medical record using electronic portals almost identical to the one used in our intervention," wrote Dr Thomas D Sequist, Brigham and Women's Hospital and Harvard Medical School, and colleagues, in a statement release.

Very Few People Know How To Protect Yourself From Skin Cancer

Very Few People Know How To Protect Yourself From Skin Cancer.
A uncharted nationwide survey by the American Academy of Dermatology finds that many tribe don't know enough about sun damage to protect themselves from developing skin cancer. "Our inspection showed that despite our repeated warnings about the dangers of UV exposure and the importance of proper Sol protection, many people could not correctly answer true/false statements on the subject," said dermatologist Dr Zoe D Draelos, consulting professor at Duke University School of Medicine in Durham, NC, in a report release.

The inquiry found that only about one-third of more than 7000 people surveyed knew that neither ultraviolet A nor ultraviolet B rays are sure for your skin. "Quite simply, all forms of UV exposure, whether from talent sunlight or artificial light sources found in tanning beds, are unsafe and are the No 1 preventable hazard factor for skin cancer".

Mortality From Lung Cancer Is Several Times Higher Than From Cancer Of Other Organs

Mortality From Lung Cancer Is Several Times Higher Than From Cancer Of Other Organs.
Lung cancer is the most mortal tint of cancer in the United States, extermination about 157,300 people every year - more than colon, breast and prostate cancer combined, according to the US National Institutes of Health. It is also the nation's later unequalled cause of death, second only to heart disease. And yet lung cancer attracts fewer federal scrutinize dollars per death than the other leading forms of cancer demise. Doctors have yet to repossess a reliable method for screening for lung cancer.

And new treatments for lung cancer rocking out at a snail's pace compared with therapies for other cancers. So why does the top cancer killer captivate so little attention? Largely because people are perceived to have done this to themselves, garnering little public sympathy, said Kay Cofrancesco, big cheese of advocacy relations for the Lung Cancer Alliance, a subject nonprofit group dedicated to lung cancer support and advocacy. About 90 percent of men and 80 percent of women who Euphemistic depart from lung cancer are current or former smokers, according to NIH.

And "In demonizing the tobacco companies, we've then demonized the smoker. So there is that blame-the-victim capacity when it comes to lung cancer patients". Yet some advances are being made. Clinical trials are being conducted on one possible screening embellish for lung cancer.

Targeted therapies are being developed based on the genetics of lung cancer. But starkly more can be done, experts say. Survival rates for lung cancer are gloomy compared with other cancers, largely because lung cancer is most often not detected until it has metastasized.

And "Some lung cancers have a movement to spread widely throughout the body," said Dr Len Lichtenfeld, substitute chief medical officer of the American Cancer Society. "By the time they have symptoms, the cancer has spread". Because smoking is so closely linked to lung cancer, most boodle aimed at frustrating has gone into programs to promote smoking cessation.

These programs have not made a lot of headway. Between 1998 and 2008, the part of US residents who currently smoked declined just 3,5 percent, from 24,1 to 20,6 percent, according to the US Centers for Disease Control and Prevention. Even as some settle quit, as the case may be encouraged by strict smoke-free laws and public anti-smoking campaigns, others stand up the habit. Quitting smoking does provide numerous health benefits - improved lung gala and decreased blood pressure among them - but former smokers will always have an elevated gamble for developing lung cancer.

New Evidence On The Relationship Between Smoking And Cancer

New Evidence On The Relationship Between Smoking And Cancer.
Men who suppress smoking after being diagnosed with cancer are more in all probability to die than those who quit smoking, a young study shows. The findings demonstrate that it's not too late to stop smoking after being diagnosed with cancer, researchers say. They reach-me-down data from a study conducted in China middle men aged 45 to 64, starting between 1986 and 1989.

Researchers determined that more than 1600 surrounded by them had developed cancer by 2010. Of those men, 340 were nonsmokers, 545 had quit smoking before their cancer diagnosis and 747 were smokers at the chance they were diagnosed. Among the smokers, 214 discharged after diagnosis, 336 continued to smoke occasionally and 197 continued to smoke regularly. Compared to men who did not smoke after a cancer diagnosis, those who smoked after diagnosis had a 59 percent higher peril of destruction from all causes.

Popular Drugs To Lower Blood Pressure Increases The Risk Of Cancer

Popular Drugs To Lower Blood Pressure Increases The Risk Of Cancer.
Use of a acclaimed realm of drugs for high blood pressure and pith failure is associated with a slight boost in cancer risk, a new review of data finds. The drugs are known as angiotensin-receptor blockers (ARBs) and encompass medicines such as telmisartan (Micardis), losartan (Cozaar, Hyzaar), valsartan (Diovan) and candesartan (Atacand). Overall, the researchers looked at trials involving over 223000 patients. When they concentrated on five trials involving over 60000 patients, in which cancer was a pre-specified endpoint, "patients assigned to these ARBs had about a 10 percent expand in cancer" germane to those not on the medications, said Dr Ilke Sipahi, subsidiary professor of cure-all at Case Western Reserve University, leading lady author of a report in the June 14 online printing of The Lancet Oncology.

The incidence of cancer in people taking an ARB was 7,2 percent, compared to a 6 percent rate in those taking a placebo, the analysis found. The increase in well-made tumors was concentrated in lung cancers, whose incidence was 25 percent higher in those taking an ARB. Despite the addition in risk, the researchers noted that there was only a slight increase in deaths from cancer among ARB users - 1,8 percent for those taking ARBs, 1,6 percent for those taking placebo, a nature that was not statistically significant.

Most of the kith and kin in the trials - 85,7 percent - were taking the ARB telmisartan (Micardis), while the residuum took other ARBs such as losartan, valsartan and candesartan. The drugs work by blocking apartment receptors for angiotensin II, a hormone that plays an important role in regulating blood pressure. Another discernment of drugs that are used for the same purposes are the ACE inhibitors, which prevent the configuration of the active form of angiotensin. "Experimental studies using cancer cell lines and animal models have implicated the angiotensin set-up in the proliferation of cells and also tumors. Evidence from animal studies show that blockage of angiotensin receptors can provoke tumor growth by promoting new blood vessel appearance in tumors".

But the evidence that ARBs can play a real role in cancer growth remains unclear and these findings only show an association, not cause-and-effect. "Before we elevation to that conclusion, I feel we need more analysis".

New Blood Test Can Detect Prostate Cancer More Accurately And Earlier

New Blood Test Can Detect Prostate Cancer More Accurately And Earlier.
A untrodden blood probe to spot a cluster of specific proteins may evidence the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a lead study, is 90 percent accurate and returned fewer false-positive results than the prostate fixed antigen (PSA) test, which is the current clinical standard, the researchers added. Representatives of the British public limited company that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.

The examine looks for auto-antibodies for cancer, alike to the auto-antibodies associated with autoimmune diseases such as variety 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's transgression president of biomarker discovery. "We're tiring to look for antibodies generated in the beginning stages of cancer. This is an exquisitely sensitive mechanism that we're exploring with this technology".

Such a study generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a unassuming blood test". The researchers came up with groups of up to 15 biomarkers that were exhibit in prostate cancer samples and not present in men without prostate cancer. The exam also was able to differentiate actual prostate cancer from a more benign condition.

Because a apparent is currently pending, Anson would not list the proteins included in the test. "We are prosperous on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a well range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".

PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer

PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer.
A approach that urologists had hoped would prepare it credible to distinguish men with prostate cancer who need treatment from those who would only need watchful waiting didn't function well, researchers report. The technique, called PSA kinetics, measures changes in the deserve at which the prostate gland produces a protein called prostate-specific antigen. A significant enhancement in PSA kinetics, measured by the time during which PSA production doubles or increases at a fast rate, is supposed to indicate the need for treatment, by radiation therapy or surgery.

PSA kinetics has covet been used to measure the effectiveness of treatment. A number of cancer centers have started to use it as a reasonable method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be left alone.

Recent studies indicating that many men with slow-growing prostate cancers be subjected to unnecessary treatment have given stress to the search for such a tool, especially considering that side effects of treatment can include incontinence and impotence. But the ponder indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr Ashley E Ross, a urology dwelling at the Johns Hopkins University Brady Urological Institute, and move author of a report on the technique published online May 3 in the Journal of Clinical Oncology.

The promulgate describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer - the amicable that often doesn't require treatment - for an average of 2,9 years. The results of PSA tests were compared with biopsies - pack samples - that regular the progression of the cancers.

The trial is part of a study, under supervision of Dr H Ballentine Carter, kingpin of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the whirl had PSA tests every six months and biopsies every year.

Doctors Recommend A New Treatment For Cancer

Doctors Recommend A New Treatment For Cancer.
The remedy Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at tainted risk for the disease, according to a new study Dec 2013. The finding, scheduled for appearance Thursday at the San Antonio Breast Cancer Symposium in Texas, adds count that Arimidex (anastrozole) might be a valuable new preventive option for some women. The study will also be published in the journal The Lancet.

So "Two other antihormone therapies, tamoxifen and raloxifene, are in use by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which determine their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will outstrip to an alternative prevention therapy with fewer string effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, climax of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

About 80 percent of US bust cancer patients have tumors with expensive levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore cast-off to treat postmenopausal women with hormone receptor-positive titty cancer. The study included more than 3800 postmenopausal women at increased endanger for breast cancer due to having two or more blood relatives with breast cancer, having a innate or sister who developed breast cancer before age 50, or having a nourish or sister who had breast cancer in both breasts.

Cancer Risk From CT Scans Lower Than Previously Thought

Cancer Risk From CT Scans Lower Than Previously Thought.
The chance of developing cancer as a development of radiation exposure from CT scans may be drop than previously thought, new research suggests. That finding, scheduled to be presented Wednesday at the annual congregation of the Radiological Society of North America in Chicago, is based on an eight-year criticism of Medicare records covering nearly 11 million patients. "What we found is that overall between two and four out of every 10000 patients who live a CT scan are at risk for developing secondary cancers as a result of that shedding exposure," said Aabed Meer, an MD candidate in the department of radiology at Stanford University in Palo Alto, Calif. "And that risk, I would say, is bring than we expected it to be".

As a result, patients who for a CT scan should not be fearful of the consequences, Meer stated. "If you have a iota and need a CT scan of the head, the benefits of that scan at that moment outweigh the very child possibility of developing a cancer as a result of the scan itself. CT scans do amazing things in terms of diagnosis. Yes, there is some emanation risk. But that small risk should always be put in context".

The authors set out to quantify that jeopardize by sifting through the medical records of elderly patients covered by Medicare between 1998 and 2005. The researchers separated the statistics into two periods: 1998 to 2001 and 2002 to 2005. In the earlier period, 42 percent of the patients had undergone CT scans. For the patch 2002 to 2005, that illustration rose to 49 percent, which was not surprising given the increasing use of scans in US medical care.

Within each group, the analyse team reviewed the number and quintessence of CT scans administered to see how many patients received low-dose radiation (50 to 100 millisieverts) and how many got high-dose diffusion (more than 100 millisieverts). They then estimated how many cancers were induced using yardstick cancer risk models.

Daily Long-Term Use Of Low-Dose Aspirin Reduces The Risk Of Death From Various Cancers

Daily Long-Term Use Of Low-Dose Aspirin Reduces The Risk Of Death From Various Cancers.
Long-term use of a common low-dose aspirin dramatically cuts the hazard of failing from a wide array of cancers, a new investigation reveals. Specifically, a British investigate team unearthed evidence that a low-dose aspirin (75 milligrams) captivated daily for at least five years brings about a 10 percent to 60 percent decline in fatalities depending on the type of cancer. The finding stems from a fresh analysis of eight studies involving more than 25,500 patients, which had from the outset been conducted to examine the protective potential of a low-dose aspirin regimen on cardiovascular disease.

The up to date observations follow prior research conducted by the same bone up team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the gamble of dying from colorectal cancer by a third. "These findings provide the first proof in people that aspirin reduces deaths due to several common cancers," the study team noted in a news release.

But the study's go first author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that "these results do not show that all adults should immediately start taking aspirin. They do picket major new benefits that have not previously been factored into guideline recommendations," he added, noting that "previous guidelines have rightly cautioned that in nutritious middle-aged people, the small risk of bleeding on aspirin partly offsets the aid from prevention of strokes and heart attacks".

And "But the reductions in deaths due to several stock cancers will now alter this balance for many people," Rothwell suggested. Rothwell and his colleagues published their findings Dec 7, 2010 in the online issue of The Lancet. The delving involved in the current review had been conducted for an average period of four to eight years.

Annually Mammography For Older Women Significantly Reduces The Likelihood That It Would Be Necessary Mastectomy

Annually Mammography For Older Women Significantly Reduces The Likelihood That It Would Be Necessary Mastectomy.
Yearly mammograms for women between the ages of 40 and 50 dramatically bring down the take place that a mastectomy will be life-and-death if they develop breast cancer, a untrained study suggests. British researchers studied the records of 156 women in that seniority range who had been diagnosed with breast cancer between 2003 and 2009, and treated at the London Breast Institute. Of these women, 114 had never had a mammogram and 42 had had at least one mammogram within the at two years, including 16 who had had a mammogram within one year.

About 19 percent of the women who'd been screened within one year had a mastectomy, the deliberate over found, compared with 46 percent of those who had not had a mammogram the premature year. Because annual mammograms allowed tumors to be discovered earlier, breast-sparing surgery was attainable for most of the women, said Dr Nicholas M Perry, the study's premier author. Perry, pilot of the institute, at the Princess Grace Hospital in London, was to present the study findings Wednesday in Chicago at the annual engagement of the Radiological Society of North America.

And "You're talking about lowering the mob of mastectomies by 30 percent. That's 2000 mastectomies in the UK every year, and in the US, that's over 10000 mastectomies saved in a year. The numbers are big and impressive, and chest cancer in minor women is a very big issue". Among all women diagnosed with breast cancer at the London institute during the inquiry period, 40 percent were younger than 50.

According to the American Cancer Society, about 207000 experimental cases of invasive breast cancer will be diagnosed in women in the United States this year. The organization recommends annual mammograms for women 40 and older, but a report in November 2009 from the US Preventive Services Task Force suggested that screenings begin at epoch 50 and be given every other year.

Laparoscopic Surgery Of The Colon Reduces The Risk Of Venous Thrombosis

Laparoscopic Surgery Of The Colon Reduces The Risk Of Venous Thrombosis.
Minimally invasive colon surgery reduces the jeopardy of blood clots in the recondite veins compared with conventional surgery, University of California, Irvine, researchers report. Deep deposit blood clots, called venous thromboembolism (VTE), occur in about a mercifulness of patients who have colorectal surgery, the researchers said. The benefits of less invasive laparoscopic surgery also number faster recovery time and a smaller scar, but these advantages may not be enough to bring about a widespread flog from traditional surgery.

And "From the cancer perspective, this does not appear to be a game changer," said Dr Durado Brooks, impresario of colorectal cancer at the American Cancer Society. Brooks said that surrounded by cancer patients in the study, no significant difference in the risk of VTE was found between the two procedures.

So "In addition, cancer had been viewed as a contraindication for laparoscopic surgery. There needs to be a more focused turn over looking exclusively at the cancer residents before anyone would promote laparoscopic surgery as the way to go for cancer patients". The clock in was published in the June issue of the Archives of Surgery.

Scientists Have Found A Link Between Diabetes And Cancer

Scientists Have Found A Link Between Diabetes And Cancer.
People with font 2 diabetes might be at moderately higher risk of developing liver cancer, according to a large, long-term scrutinize Dec 2013. The research suggests that those with type 2 diabetes have about two to three times greater gamble of developing hepatocellular carcinoma (HCC) - the most joint type of liver cancer - compared to those without diabetes. Still, the jeopardize of developing liver cancer remains low. Race and ethnicity might also play a role in increasing the probability of liver cancer, the researchers said.

An estimated 26 percent of liver cancer cases in Latino examination participants and 20 percent of cases in Hawaiians were attributed to diabetes. Among blacks and Japanese-Americans, the researchers estimated 13 percent and 12 percent of cases, respectively, were attributed to diabetes. Among whites, the gait was 6 percent. "In general, if you're a species 2 diabetic, you're at greater danger of liver cancer," said heroine author V Wendy Setiawan, an assistant professor at the Keck School of Medicine at the University of Southern California.

Yet the genuine risk of liver cancer - even for those with type 2 diabetes - is still extraordinarily low, said Dr David Bernstein, paramount of hepatology at North Shore University Hospital in Manhasset, NY Although liver cancer is comparatively rare, it has been on the grow worldwide and often is associated with viral hepatitis infections and liver diseases, such as cirrhosis. New cases of HCC in the United States have tripled in the since 30 years, with Latinos and blacks experiencing the largest increase.

During that time, prototype 2 diabetes also has become increasingly common. What might the consistency be? It's possible that the increased risk of liver cancer could be associated with the medications clan with diabetes take to control their blood sugar, said Dr James D'Olimpio, an oncologist at Monter Cancer Center in Lake Success, NY "Some medications are known to frustrate natural suppression of cancer. "Some of the drugs already have US Food and Drug Administration-ordered funereal box warnings for bladder cancer," D'Olimpio said.

And "It's not a increase to think there might be other relationships between diabetes drugs and pancreatic or liver cancer. Diabetes is already associated with a far up risk of developing pancreatic cancer". People with type 2 diabetes often develop a fit called "fatty liver," D'Olimpio said. In these cases, the liver has trouble handling the plentifulness of fat in its cells and gradually becomes inflamed.